Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 11/20 | 0.76 |
| ▸ | RAB9A | P51151 | 10/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | MLLT1 | Q03111 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | MLLT3 | P42568 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661429 | 0.86 | NPC1 (1.00) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL11931680 | 0.84 | NPC1 (1.00) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL11931686 | 0.84 | NPC1 (1.00) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL14160551 | 0.82 | TRPV1 (0.70) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL18618367 | 0.82 | MLLT1 (0.95) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL13902147 | 0.82 | S1PR1 (1.00) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL17933816 | 0.81 | NPC1 (0.95) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL18616978 | 0.79 | NPC1 (0.73) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL15099490 | 0.78 | NPC1 (0.90) | TRPV1NPC1RAB9ATDP1MLLT1 | |
| SCHEMBL31604666 | 0.77 | TRPV1 (0.63) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211927-B2 | 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators | MSD, Oss B.V. (NL) | 2012-07-03 | — | — | US | disclosed |
| EP-2185530-B1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | ORGANON NV (NL) | 2011-09-14 | — | — | EP | disclosed |
| US-20110065764-A1 | 5- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. Organon and Pharmacopeia, LLC (NL) | 2011-03-17 | — | — | US | disclosed |
| WO-2009016241-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. ORGANON (NL) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065764-A1 | 5- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | TRPV1, TRPV5, TRPV3 | TRPV1 1/4885NPC1 1617/4885RAB9A 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.